Ardelyx, Inc. (NASDAQ:ARDX) Citi’s Biopharma Back to School Conference September 3, 2025 1:00 PM EDT
Company Participants
Michael Raab – President, CEO & Director
Eric Foster – Chief Commercial Officer
Justin Renz – Chief Financial & Operations Officer
Conference Call Participants
Yigal Nochomovitz – Citigroup Inc., Research Division
Presentation
Yigal Nochomovitz
Director and SMid Cap Biotech Analyst
We’re going to start the afternoon session. I’m Yigal Nochomovitz, biotech analyst at Citi. This is our back-to-school Biopharma Summit in Boston. If you have questions, if you’re in the audience, just know you can chime in with the microphones. And also for those listening online, welcome. So the next session is with Ardelyx. And I have with me the senior management, Mike Raab, President and CEO; Justin Renz, CFO; and Eric Foster, CCO. So thank you all very much. Great to see you. Thanks for coming in.
Question-and-Answer Session
Yigal Nochomovitz
Citigroup Inc., Research Division
So I guess maybe to start out, Mike, if you want to just kind of summarize where you are with the business, 2 products that are gaining momentum.
Michael Raab
President, CEO & Director
Sure. Thanks, Yigal, and to Citi for inviting us. I think we’re at an incredibly exciting time for the evolution of the company where you look at the decision that we made to not participate in TDAPA. First, let’s get that off the table because that’s certainly a question that we get a lot of that, that strategy is working. We’re seeing since February month-over-month growth of prescriptions. And you see the total prescriptions, whether they are patient assistance and commercial and Medicaid that we’re reading — that we’re meeting the place where we’ve had more prescriptions written than previous months.
So the growth is there. Is it growing as fast as we would like? Not
Read the full article here
